We at Tiefenbacher Pharmaceuticals strongly believe that our high-quality medicines should be affordable and available for all patients around the world – irrespective of their nationality or income. That´s why we are thrilled to share that we have successfully prepared a day one launch of the generic version of Ezetimibe/Atorvastatin in 12 European markets.

Ezetimibe/Atorvastatin is used to reduce the production of cholesterol in the liver. Furthermore it helps to limit the absorption of cholesterol from the intestines. This dual action approach has the potential to lower LDL cholesterol (“bad” cholesterol), which could offer cardiovascular benefits, particularly for patients at risk of heart disease or stroke. The combination of Atorvastatin and Ezetimibe is a treatment option that is frequently considered by healthcare providers to treat patients with high cholesterol, especially those who are unresponsive to single-agent therapy. By offering this affordable medicine, we are providing a valuable option for those in need. At the same time, we can really make a difference in improving the lives of patients. The tablets are marketed in the strengths of 10mg/10mg, 10mg/20mg, 10mg/40mg, and 10mg/80mg

This launch reflects our ongoing commitment to providing patients with high-quality, cost-effective medications and is a testament to the hard work and commitment of our team

In case of inquiries please reach out to licensing@tiefenbacher.com